A new Precision Health Economics-authored study on the societal value of CAR-T therapy is generating a significant level of interest within the scientific community. PHE’s Julia Snider touches on some of the key takeaways of the study, presented at this year’s ASH, with the American Journal of Managed Care.

To read the complete article including Julia’s comments, please click here.